Skip Navigation


Cardiovascular Research Advance Access originally published online on November 13, 2007
Cardiovascular Research 2008 77(3):481-488; doi:10.1093/cvr/cvm069
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
77/3/481    most recent
cvm069v2
cvm069v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Wu, L.
Right arrow Articles by Belardinelli, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wu, L.
Right arrow Articles by Belardinelli, L.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2007. For permissions please email: journals.permissions@oxfordjournals.org

Augmentation of late sodium current unmasks the proarrhythmic effects of amiodarone

Lin Wu1,*, Sridharan Rajamani1, John C. Shryock1, Hong Li1, Jeremy Ruskin2, Charles Antzelevitch3 and Luiz Belardinelli1

1 Department of Pharmacological Sciences, CV Therapeutics, Inc. 3172 Porter Drive, Palo Alto, CA 94304, USA
2 Cardiac Arrhythmia Service, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
3 Masonic Medical Research Laboratory, Utica, NY, USA

* Corresponding author. Tel: +1 650 384 8624; fax: +1 650 475 0393. E-mail address: lin971{at}yahoo.com

Aim: Clinical use of amiodarone is associated with occasional development of torsade de pointes (TdP). However, preclinical models have failed to demonstrate the proarrhythmic potential of amiodarone. The objective of this study was to reveal and explain the pro- and anti-arrhythmic effects of acute exposure to amiodarone in an animal model.

Methods and results: Endo- and epicardial monophasic action potentials (MAPs) and 12-lead electrocardiogram were recorded in female rabbit isolated hearts. Ion channel currents were measured in human embryonic kidney cells expressing SCN5A Na+ and HERG K+ channels. Acute amiodarone alone caused an insignificant increase in duration of MAP (MAPD90) without causing TdP. In the presence of 3 nM sea anemone toxin (ATX-II), amiodarone (1–30 nM) prolonged MAPD90 from 217 ± 5 to 250 ± 8 ms (n = 16, P < 0.01), increased transmural dispersion of repolarization (TDR) from 59 ± 9 to 70 ± 10 ms and beat-to-beat variability (BVR) of MAPD90 from 0.75 ± 0.03 to 1.06 ± 0.13 ms (P < 0.05). At 30–300 nM, amiodarone induced TdP in 16 out of 17 hearts. A further increase of amiodarone concentration to 1–10 µM abbreviated MAPD90 to 211 ± 9 ms, decreased BVR to 0.5 ± 0.01 ms, decreased TDR (n = 7, P < 0.05), and suppressed TdP. Amiodarone inhibited HERG K+ and late Na+ currents with IC50s of 0.8 ± 0.1 and 3.0 ± 0.9 µM, respectively.

Conclusion: In hearts in which late INa is augmented to mimic congenital or acquired pathological conditions, amiodarone has a concentration-dependent biphasic effect to induce and then suppress arrhythmic activity, secondary to inhibition of HERG K+ and late Na+ currents. This is the first preclinical model demonstrating the potential for amiodarone to induce TdP.

KEYWORDS Antiarrhythmic agents; Arrhythmia (mechanism); Ion channels; Long QT syndrome; Membrane potentials


Time for primary review: 21 days


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.